摘要
目的系统评价昆仙胶囊单用或联合甲氨蝶呤(MTX)治疗类风湿关节炎(RA)的临床疗效。方法系统检索中国知网(CNKI)、万方数据库、重庆维普数据库、PubMed、EMbase、Cochrane Library数据库(建库至2020年2月)昆仙胶囊单独用药或联合用药治疗RA的随机对照试验(RCTs)文献,对符合纳入标准的文献应用Cochrane协作网推荐的RevMan 5.3对所提取的数据进行统计学分析。结果纳入6篇文献,共532例病例。昆仙胶囊联合MTX治疗RA总有效率优于MTX对照组[OR=3.40,95%CI=(1.88,6.17),P<0.00001],差异有统计学意义,且在改善类风湿因子(RF)、血沉(ESR)、C反应蛋白(CRP)、晨僵时间、关节疼痛数、关节肿胀数方面优于对照组。结论昆仙胶囊联用MTX治疗类风湿关节炎疗效显著,但仍需更多高质量的随机对照研究加以证实。
Objective To systematically evaluate the clinical efficacy of Kunxian Capsule(KXC)alone or in combination with methotrexate(MTX)in the treatment of rheumatoid arthritis(RA).Methods Six databases CNKI,Wanfang,Weipu,PubMed,EMBASE,Cochrane Library(the database was built until February 2020)were searched systematically.The RCT literatures of Kunxian capsule alone or in combination for RA treatment were analyzed by Revman 5.3 recommended by Cochrane Collaboration Network.Results In this study,6 articles were included,including 532 cases.The total effective rate of Kunxian capsule combined with methotrexate group was better than that of MTX control group,the difference was statistically significant(OR=3.40,95%CI=[1.88,6.17],P<0.00001).RF,ESR,CRP,morning stiffness time,joint pain and joint swelling were better than that of control group in.Conclusion Kunxian capsule with MTX has a significant effect on rheumatoid arthritis.But more high-quality randomized controlled studies are needed to confirm it.
作者
王欣妍
曹晔文
许涛
曹炜
WANG Xin-yan;CAO Ye-wen;XU Tao;CAO Wei(Department of Rheumatology,Guang′anmen Hospital,Chinese Academy of Traditional Chinese Medicine,Beijing 100053;Beijing University of traditional Chinese medicine,Beijing 100029)
出处
《世界中西医结合杂志》
2021年第2期254-258,263,共6页
World Journal of Integrated Traditional and Western Medicine
基金
国家重点研发计划资助项目(2018YFC1705500)。
